Diffuse Large B-cell Lymphoma Therapeutics Market Impacted by COVID

COVID 19 Impact on Patients

The COVID-19 pandemic continues to endanger global health and hinder the world economy; It has been widely observed that patients with existing diffuse large b-cell lymphoma experience higher complications due to COVID-19. 

The degree to which ongoing chemotherapy impacts the outcome of patients with COVID-19 remains controversial, but at least one large study shows that individuals with diffuse large b-cell lymphoma undergoing treatment when diagnosed with COVID-19 are at high risk of severe complications.  

There are also data suggesting that patients with lymphoma have an increased susceptibility to infection with SARS-CoV-2. According to one report, the more intense the therapy, the greater the impact on clinical outcomes in patients who contract COVID-19. The high morbidity and mortality rates reported in patients with hematologic malignancies underscore the vulnerability of this patient population.

Most centers are screening patients beginning therapy in the out-patient clinic or even monthly on an on-going basis, or on admission to the hospital for treatment. Practices differ depending on the prevalence of COVID-19 and the availability of screening. The decision on when and how to treat in the face of a positive result must be individualized.

Patients with diffuse large b-cell lymphoma who are actively undergoing treatment with an anti-CD20 antibody have an impaired response to the BNT162b2 mRNA (by Pfizer-BioNTech) COVID-19 vaccine, according to research published in Blood Advances.

Patients who had any exposure to anti-CD20 therapy were less likely to have a response to the COVID-19 vaccine. Patients with an absolute lymphocyte count were also less likely to respond to the vaccine. This will create problem for patients who are presently taking therapies.

COVID 19 Impact on Companies 

As COVID-19 continues to wreak havoc on global healthcare, pharmaceutical companies are well positioned to proactively support oncologists and cancer patients.

The pandemic has directly affected the supply of diffuse large b-cell lymphoma drugs to patients, not only is it difficult to administer chemotherapy and certain other treatments outside of a clinic, but the spread of coronavirus has reduced patients’ willingness and ability to access not just treatments, but trials for new medicines.

COVID-19’s interference with the research and development of new treatments is one of the most significant blows that has been dealt to the diffuse large b-cell lymphoma market. Pharma focus the pandemic initially drew recruitment for UK clinical trials to an almost complete halt. 

From about April last year until July or August time, all British hospitals stopped recruiting patients into new clinical trials. There was also a complete block on opening new trials.

In R&D, the rapid implementation of multiple digital technologies has led to real-time monitoring of trials around the world, where recruitment or medicines supply might be impacted, and permitting proactive countermeasures to quickly ensure continuity.

About Us:

DataM Intelligence was incorporated in the early weeks of 2017 as a Market Research and Consulting firm with just two people on board. Within a span of less than a year, we have secured more than 100 unique customers from established organizations all over the world.

For more information:

Sai Kiran

Sales Manager at DataM Intelligence

Email: [email protected]

Tel: +1 877 441 4866

Website: www.datamintelligence.com